News for Healthier Living

FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two groups of patients with previously treated NETs: advanced pancreatic NETs and advanced extra-pancreatic NETs. The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

March 26, 2025


April 6 2025

April 5 2025

April 4 2025

April 3 2025

April 2 2025

April 1 2025

March 31 2025

March 30 2025

March 29 2025

March 28 2025

March 27 2025

March 26 2025

March 25 2025

March 24 2025

March 23 2025